Search Result

Results for "

ROCK

" in MedChemExpress (MCE) Product Catalog:

By Targets:	ROCK (158) ADC Payloads (1) Akt (7) AMPK (2) Apoptosis (15) Autophagy (11) Calcium Channel (7) Caspase (2) Cdc42-binding kinase (1) CDK (1) Collagen (1) DNA/RNA Synthesis (2) Drug Intermediate (4) Drug Metabolite (1) Endogenous Metabolite (2) Epigenetic Reader Domain (3) ERK (5) FASTK (2) FOXO (1) G Protein-coupled Receptor Kinase (GRK) (10) GPR55 (1) GSK-3 (1) HDAC (2) HIV (4) HSP (1) IGF-1R (1) Indoleamine 2,3-Dioxygenase (IDO) (2) Isotope-Labeled Compounds (2) Keap1-Nrf2 (2) LDLR (2) LIM Kinase (LIMK) (4) LPL Receptor (1) Mas-related G-protein-coupled Receptor (MRGPR) (1) Mitochondrial Metabolism (2) MMP (1) Monoamine Transporter (1) mTOR (3) Myosin (5) NADPH Oxidase (3) NF-κB (7) Opioid Receptor (1) Organoid (2) p38 MAPK (6) PAK (3) PI3K (3) PKA (15) PKC (20) PTEN (1) Ras (4) Reactive Oxygen Species (ROS) (5) Reference Standards (20) Ribosomal S6 Kinase (RSK) (3) SGK (1) Sirtuin (2) Small Interfering RNA (siRNA) (6) STAT (4) TGF-beta/Smad (3) TGF-β Receptor (1) Toll-like Receptor (TLR) (2) β-catenin (1)
By Research Areas:	Cancer (79) Cardiovascular Disease (45) Endocrinology (3) Inflammation/Immunology (44) Metabolic Disease (9) Neurological Disease (41)
Oligonucleotides:	Rat Pre-designed siRNA Sets (2) Mouse Pre-designed siRNA Sets (2) Human Pre-designed siRNA Sets (2) siRNAs (6)

181

Inhibitors & Agonists

Screening Libraries

Fluorescent Dyes

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Oligonucleotides

GMP Molecules

Targets Recommended: ROCK

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-10583

Y-27632 dihydrochloride 555+ Cited Publications	Organoid ROCK	Neurological Disease Cancer
Y-27632 dihydrochloride is an orally active and ATP-competitive *ROCK* (Rho-kinase) inhibitor (ROCK-I K_i=220 nM; ROCK-II K_i=300 nM). Y-27632 dihydrochloride shows antiepileptic effects .

HY-15392

Chroman 1 65+ Cited Publications	ROCK	Cardiovascular Disease
Chroman 1 is a highly potent and selective *ROCK* inhibitor. Chroman 1 is more potent against ROCK2 (IC₅₀=1 pM) than ROCK1 (IC₅₀=52 pM). Chroman 1 also has inhibitory activity against MRCK, with an IC₅₀ of 150 nM .

HY-15307

Belumosudil 30+ Cited Publications KD025; SLx-2119	ROCK	Inflammation/Immunology Cancer
Belumosudil (KD025) is a selective inhibitor of *ROCK2* with IC₅₀s of 105 nM and 24 μM for ROCK2 and ROCK1, respectively. Anti-fibrotic properties .

HY-15556

GSK269962A 5+ Cited Publications GSK 269962	ROCK	Cardiovascular Disease Inflammation/Immunology
GSK269962A (GSK 269962) is a potent *ROCK* inhibitor with IC₅₀s of 1.6 and 4 nM for recombinant human *ROCK1* and *ROCK2* respectively. GSK269962A has anti-inflammatory and vasodilatory activities .

HY-10583R

Y-27632 dihydrochloride (Standard) 555+ Cited Publications	ROCK Organoid Reference Standards	Cancer
Y-27632 dihydrochloride (Standard) is the analytical standard of Y-27632 dihydrochloride. Y-27632 dihydrochloride is an orally active and ATP-competitive *ROCK* (Rho-kinase) inhibitor (ROCK-I K_i=220 nM; ROCK-II K_i=300 nM). Y-27632 dihydrochloride shows antiepileptic effects .

HY-15307A

Belumosudil mesylate 30+ Cited Publications KD025 mesylate; SLx-2119 mesylate	ROCK	Inflammation/Immunology
Belumosudil mesylate (KD025 mesylate) is a selective inhibitor of *ROCK2* with IC₅₀s of 105 nM and 24 µM for ROCK2 and ROCK1, respectively. Anti-fibrotic properties .

HY-119937

ROCK inhibitor-2 2 Publications Verification	ROCK	Cardiovascular Disease Inflammation/Immunology Cancer
ROCK inhibitor-2 (compound 6) is a selective dual inhibitor of ROCK1 and ROCK2, with IC₅₀ values of 160 nM and 21 nM, respectively. ROCK inhibitor-2 inhibits pMYPT1 with IC₅₀ of 75 nM. ROCK inhibitor-2 exhibits antitumor activity .

HY-10319

BAY-549 4 Publications Verification ROCK-IN-2; Azaindole 1; TC-S 7001	ROCK	Cardiovascular Disease
BAY-549 (Azaindole 1), a chemical probe, is an orally active and ATP-competitive *ROCK* inhibitor with IC₅₀s of 0.6 and 1.1 nM for human *ROCK-1* and *ROCK-2*, respectively .

HY-15685

Ripasudil 5+ Cited Publications K-115	ROCK	Cardiovascular Disease Neurological Disease
Ripasudil (K-115) is a specific inhibitor of *ROCK, with IC₅₀s of 19 and 51 nM for ROCK2* and *ROCK1*, respectively.

HY-15720A

H-1152 dihydrochloride 5 Publications Verification	ROCK	Neurological Disease
H-1152 dihydrochloride is a membrane-permeable and selective *ROCK* inhibitor, with a K_i value of 1.6 nM, and an IC₅₀ value of 12 nM for *ROCK2*.

HY-15755

RKI-1447 4 Publications Verification	ROCK	Cancer
RKI-1447 is a potent small molecule inhibitor of *ROCK1* and *ROCK2* with IC₅₀ values of 14.5 nM and 6.2 nM, respectively.

HY-12798B

Netarsudil hydrochloride 1 Publications Verification AR-13324 hydrochloride	ROCK	Cardiovascular Disease Neurological Disease
Netarsudil (AR-13324) hydrochloride is a competitive inhibitor of Rho-associated protein kinases (ROCK I and ROCK II) and a reversible inhibitor of the norepinephrine transporter (NET). Netarsudil hydrochloride reduces intraocular pressure by inhibiting *ROCK*, causing relaxation of trabecular meshwork cells and dilation of episcleral veins, thereby increasing the ease of aqueous humor outflow, while inhibiting NET to reduce aqueous humor production. Netarsudil hydrochloride is mainly used in the study of ocular hypertension and primary open-angle glaucoma .

HY-15687A

SAR407899 3 Publications Verification	ROCK	Metabolic Disease
SAR407899 is a selective, potent and ATP-competitive *ROCK* inhibitor, with an IC₅₀ of 135 nM for *ROCK-2, and K_is of 36 nM and 41 nM for human and rat ROCK-2*, respectively. SAR407899 shows stable inhibition of migrasome formation.

HY-162596

NRL-1049 BA-1049 free base	ROCK	Neurological Disease
NRL-1049 (BA-1049 (free base)) is an orally available and selective *ROCK2* inhibitor with IC₅₀ values of 0.59 µM for ROCK2 and 26 µM for ROCK1, respectively. NRL-1049 modulates ROCK signaling, preserves blood-brain barrier integrity, reduces edema, seizures and hemorrhage, and alleviates cerebral cavernous malformation lesion burden. NRL-1049 can be used for the study of acute brain injury, ischemic stroke, and cerebral cavernous malformations .

HY-13911

Hydroxyfasudil 5 Publications Verification HA-1100	ROCK	Cardiovascular Disease Inflammation/Immunology Cancer
Hydroxyfasudil is a *ROCK* inhibitor, with IC₅₀s of 0.73 and 0.72 μM for *ROCK1* and *ROCK2*, respectively.

HY-15720

H-1152 5 Publications Verification	ROCK	Neurological Disease
H-1152 is a membrane-permeable and selective *ROCK* inhibitor, with a K_i value of 1.6 nM, and an IC₅₀ value of 12 nM for *ROCK2*.

HY-103620

ROCK2-IN-2	ROCK	Inflammation/Immunology Cancer
ROCK2-IN-2 (Example 2) is a *ROCK2* inhibitor that can be used for the study of multiple medical disorders, such as fibrosis, inflammatory disorders, autoimmune disorders, and cardiovascular disorders .

HY-139170

CAY10746	ROCK	Metabolic Disease
CAY10746 is a selective Rho kinase (ROCK) inhibitor. CAY10746 has inhibitory activity for ROCK I, ROCK II with IC₅₀ values of 0.014 μM and 0.003 μM, respectively. CAY10746 can be used for the research of diabetic retinopathy (DR) .

HY-32951

2-Fluoropyridine-4-boronic acid	Drug Intermediate	Others
2-Fluoropyridine-4-boronic acid is a coupling reagent and chemical intermediate. 2-Fluoropyridine-4-boronic acid facilitates the synthesis of Rho kinase (ROCK) inhibitor Compound 37 .

HY-16758

Verosudil AR-12286	ROCK	Neurological Disease
Verosudil (AR-12286) is a *ROCK* inhibitor. Verosudil has equal inhibitory activity against ROCK1 and ROCK2 (K_i: 2 nM). Verosudil is less selective for PKA, PKCT, MRCKA, and CAM2A (K_i: 69 nM, 9322 nM, 28 nM, 5855 nM, respectively). Verosudil increases trabecular outflow capacity to reduce intraocular pressure. Verosudil is useful in the study of glaucoma and ocular hypertension .

HY-13911A

Hydroxyfasudil hydrochloride 5 Publications Verification HA-1100 hydrochloride; HA 1100 hydrochloride; HA1100 hydrochloride	ROCK	Cardiovascular Disease Inflammation/Immunology Cancer
Hydroxyfasudil hydrochloride is a *ROCK* inhibitor, with IC₅₀s of 0.73 and 0.72 μM for *ROCK1* and *ROCK2*, respectively.

HY-12437

BDP5290	ROCK	Cancer
BDP5290 is a potent inhibitor of both *ROCK* and MRCK with IC₅₀s of 5 nM, 50 nM, 10 nM and 100 nM for *ROCK1, ROCK2, MRCKα* and MRCKβ, respectively.

HY-15556A

GSK269962A hydrochloride 5+ Cited Publications GSK 269962 hydrochloride	ROCK	Cardiovascular Disease Inflammation/Immunology
GSK269962A hydrochloride (GSK 269962 hydrochloride) is a potent *ROCK* inhibitor with IC₅₀s of 1.6 and 4 nM for recombinant human *ROCK1* and *ROCK2* respectively. GSK269962A hydrochloride has anti-inflammatory and vasodilatory activities .

HY-100270

Rho-Kinase-IN-1	ROCK	Cancer
Rho-Kinase-IN-1 is a Rho kinase (ROCK) inhibitor (K_i values of 30.5 and 3.9 nM for ROCK1 and ROCK2, respectively) extracted from US20090325960A1, compound 1.008 .

HY-109191

Sovesudil PHP-201; AMA0076	ROCK	Others
Sovesudil (PHP-201) is a potent, ATP-competitive, locally acting Rho kinase (ROCK) inhibitor with IC₅₀s of 3.7 and 2.3 nM for ROCK-I and ROCK-II, respectively. Sovesudil lowers intraocular pressure (IOP) without inducing hyperemia .

HY-112362

3-(4-Pyridyl)indole ROCKout; 3-(4-Pyridinyl)-1H-indole; Rho Kinase Inhibitor III, ROCKout	ROCK	Inflammation/Immunology
3-(4-Pyridyl)indole (Rockout) is a Rho-kinase (ROCK) inhibitor, with an IC₅₀ of 25 μM. 3-(4-Pyridyl)indole can inhibit blebbing and cause dissolution of actin stress fibers in a wound healing assay .

HY-153569

ROCK-IN-7	ROCK	Others
ROCK-IN-7 (compound 9) is a ROCK kinase inhibitor. ROCK-IN-7 can be used for research in ocular diseases (such as glaucoma and retinal diseases) .

HY-15392A

Chroman 1 dihydrochloride 65+ Cited Publications	ROCK	Cardiovascular Disease
Chroman 1 dihydrochloride is a highly potent and selective *ROCK* inhibitor. Chroman 1 dihydrochloride is more potent against ROCK2 (IC₅₀=1 pM) than ROCK1 (IC₅₀=52 pM). Chroman 1 dihydrochloride also has inhibitory activity against MRCK, with an IC₅₀ of 150 nM .

HY-137436

Cotosudil	ROCK	Endocrinology
Cotosudil is a ROCK kinase inhibitor, which can be used for glaucoma or ocular hypertension research .

HY-108519

AS1892802	ROCK	Neurological Disease
AS1892802 is a potent, orally active, and highly selective inhibitor of *ROCK*. The onset of antinociceptive effect of AS1892802 is as fast as those of Tramadol and Diclofenac. AS1892802 did not induce gastric irritation or abnormal behavior. AS1892802 is an attractive analgesic profile for the research of severe osteoarthritis pain .

HY-15687

SAR407899 hydrochloride 3 Publications Verification	ROCK	Metabolic Disease
SAR407899 hydrochloride is a selective, potent and ATP-competitive *ROCK* inhibitor, with an IC₅₀ of 135 nM for *ROCK-2, and K_is of 36 nM and 41 nM for human and rat ROCK-2*, respectively.

HY-149266

THK01 1 Publications Verification	ROCK	Cancer
THK01 is a potent *ROCK2* inhibitor with IC₅₀ values of 5.7 and 923 nM for ROCK2 and ROCK1, respectively. THK01 inhibits breast cancer metastasis through the ROCK2-STAT3 signaling pathway. THK01 can be used in research of breast cancer .

HY-178821

ROCK2-IN-12	ROCK TGF-beta/Smad STAT	Inflammation/Immunology
ROCK2-IN-12 (Compound A25) is a selective *ROCK2* inhibitor with an IC₅₀ of 7.0  nM for ROCK2 over ROCK1. ROCK2-IN-12 has potent antifibrotic effects via the TGF-β/Smad and *ROCK2/STAT3* signaling pathways. ROCK2-IN-12 significantly reduces collagen deposition and reverses fibrotic progression in Bleomycin (HY-108345)-induced pulmonary fibrosis (PF) mouse models. ROCK2-IN-12 can be used for lung diseases like pulmonary fibrosis research .

HY-Q22471

ROCK1-IN-1 1 Publications Verification	ROCK	Cardiovascular Disease
ROCK1-IN-1 is a potent selective *ROCK1* inhibitor with a K_i of 540 nM. ROCK1-IN-1 can be used for the research of hypertension .

HY-156592A

ROCK2-IN-6 hydrochloride	ROCK	Inflammation/Immunology
ROCK2-IN-6 hydrochloride (Comp A) is a selective ROCK2 inhibitor, can be used for ROCK mediated diseases, autoimmune diseases and inflammation research .

HY-168596

*RhoA-ROCK-IN-1*	ROCK Apoptosis	Cancer
RhoA-ROCK-IN-1 (Compound b19) is an inhibitor of *RhoA/ROCK. RhoA-ROCK-IN-1 can significantly inhibit cell proliferation, migration, and invasion, while promoting cell apoptosis. RhoA-ROCK-IN-1 demonstrates remarkable anticancer activity by inhibiting the RhoA/ROCK* pathway .

HY-RS12117

ROCK2 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA) ROCK	Others
ROCK2 Human Pre-designed siRNA Set A contains three designed siRNAs for ROCK2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

ROCK2 Human Pre-designed siRNA Set A ROCK2 Human Pre-designed siRNA Set A

HY-150187

20:4 Lyso PI	GPR55 ERK ROCK Calcium Channel	Neurological Disease
20:4 Lyso PI acts as an activator of GPR55 and RhoA. 20:4 Lyso PI activates the *GPR55-RhoA-ROCK* pathway, thereby inducing morphological changes, cytoskeleton assembly, cell rounding and stress fiber formation. 20:4 Lyso PI can be used in research related to diseases such as those of the nervous system .

HY-101244

ZINC00881524	ROCK	Cancer
ZINC00881524 is a *ROCK* inhibitor.

HY-126432

NRL-1049 dihydrochloride BA-1049	ROCK	Neurological Disease
NRL-1049 dihydrochloride (BA-1049) is a selective and orally active rho-associated protein kinase 2 (ROCK2) inhibitor with an IC₅₀ of 0.59 μM. NRL-1049 dihydrochloride shows selectivity for ROCK2 is 44 times that of ROCK1 (IC₅₀ = 26 μM). NRL-1049 dihydrochloride can preserve the blood-brain barrier after acute injury .

HY-116420

ROCK2-IN-8	ROCK	Neurological Disease
ROCK2-IN-8 (Compound 1) is an orally active *ROCK2* inhibitor, with an IC₅₀ of 7.2 nM. ROCK2-IN-8 can be used for the research of aqueous humor outflow in porcine eyes and myosin light chain phosphorylation .

HY-110339

RKI-1447 dihydrochloride 4 Publications Verification	ROCK Apoptosis	Cancer
RKI 1447 dihydrochloride is a potent and selective *ROCK* inhibitor with IC₅₀s of 14.5 and 6.2 nM for *ROCK1* and *ROCK2, respectively . RKI 1447 dihydrochloride suppresses colorectal carcinoma cell growth and promotes apoptosis* .

HY-109191A

Sovesudil hydrochloride PHP-201 hydrochloride; AMA0076 hydrochloride	ROCK	Neurological Disease
Sovesudil (PHP-201) hydrochloride is a potent, ATP-competitive, locally acting Rho kinase *(ROCK)* inhibitor with IC₅₀s of 3.7 and 2.3 nM for ROCK-I and ROCK-II, respectively. Sovesudil hydrochloride lowers intraocular pressure (IOP) without inducing hyperemia .

HY-178013

ROCK2-IN-11	ROCK	Inflammation/Immunology
ROCK2-IN-11 (Compound A20) is a selective *ROCK2* inhibitor with an IC₅₀ of 0.18 μM for ROCK2 over ROCK1. ROCK2-IN-11 can be used for idiopathic pulmonary fibrosis and cGVHD research .

HY-107209

RKI-1313	ROCK	Cancer
RKI-1313 is a *ROCK* inhibitor with IC₅₀s of 34, 8 µM for ROCK 1 and ROCK 2, respectively. RKI-1313 shows little effect on the phosphorylation levels of ROCK substrates, migration, invasion or anchorage-independent growth .

HY-10068

Y-33075 hydrochloride Y-39983	ROCK	Neurological Disease
Y-33075 hydrochloride (Y-39983) is a selective *ROCK* inhibitor derived from Y-27632, and is more potent than Y-27632, with an IC₅₀ of 3.6 nM.

HY-15685A

Ripasudil free base K-115 free base	ROCK	Neurological Disease
Ripasudil free base (K-115 free base) is a specific inhibitor of *ROCK, with IC₅₀s of 19 and 51 nM for ROCK2* and *ROCK1*, respectively.

HY-126275

HSD1590	ROCK	Cancer
HSD1590 is potent *ROCK* inhibitor, with IC₅₀s of 1.22 and 0.51 nM for ROCK1 and ROCK2, respectively. HSD1590 exhibits single digit nanomolar binding to ROCK (K_ds<2 nM). HSD1590 displays low cytotoxicity .

HY-153011

ROCK-IN-5	ROCK ERK GSK-3	Cardiovascular Disease Neurological Disease
ROCK-IN-5 (compound I-B-37) is a potent inhibitor of *ROCK, ERK, GSK, and AGC* protein kinases. ROCK-IN-5 has the potential for proliferative, cardiac and neurodegenerative diseases research .

HY-U00351

ROCK-IN-1 1 Publications Verification	ROCK	Cardiovascular Disease Inflammation/Immunology
ROCK-IN-1 is a potent inhibitor of *ROCK, with an IC₅₀* of 1.2 nM for ROCK2.

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N0430

Coptisine Coptisin	Alkaloids Structural Classification Classification of Application Fields Coptis chinensis Franch. Ranunculaceae Metabolic Disease Quinoline Alkaloids Plants Disease Research Fields Source Classification	Indoleamine 2,3-Dioxygenase (IDO) NF-κB p38 MAPK PI3K Akt Apoptosis Reactive Oxygen Species (ROS) Mitochondrial Metabolism DNA/RNA Synthesis ROCK LDLR
Coptisine is an orally active and brain-penetrant alkaloid found in Coptis chinensis. Coptisine is a reversible, uncompetitive IDO inhibitor with a K_i of 5.8 μM and an IC₅₀ of 6.3 μM. Coptisine suppresses neuroinflammation, reduces Aβ plaque burden and shows neuroprotective activity. Coptisine shows anti-inflammation activity by blocking NF-κB, MAPK, and PI3K/Akt activation. Coptisine inhibits cancer cells proliferation, induces DNA damage, G2/M phase cell cycle arrest, apoptosis, ROS production and mitochondrial dysfunction. Coptisine inhibits *Rho/ROCK* pathway activation, reduces arrhythmia, limits cardiac injury marker release, reduces infarct size, and preserves cardiac function in rat myocardial ischemia/reperfusion models. Coptisine downregulates HMGCR and upregulates LDLR and CYP7A1 to modulate cholesterol metabolism, reduces abnormal serum lipid levels, and promotes fecal bile acid excretion. Coptisine can be used for the research of cancer, hypercholesterolemia, Alzheimer’s disease, inflammatory disorders and cardiovascular disease .

HY-N0430A

Coptisine Sulfate 5 Publications Verification	Alkaloids Structural Classification Chelidonium majus Classification of Application Fields Metabolic Disease Quinoline Alkaloids Plants Disease Research Fields Papaveraceae Source Classification	Indoleamine 2,3-Dioxygenase (IDO) NF-κB p38 MAPK PI3K Akt Apoptosis Reactive Oxygen Species (ROS) Mitochondrial Metabolism DNA/RNA Synthesis ROCK LDLR
Coptisine Sulfate is an orally active and brain-penetrant alkaloid found in Coptis chinensis. Coptisine Sulfate is a reversible, uncompetitive IDO inhibitor with a K_i of 5.8 μM and an IC₅₀ of 6.3 μM. Coptisine Sulfate suppresses neuroinflammation, reduces Aβ plaque burden and shows neuroprotective activity. Coptisine Sulfate shows anti-inflammation activity by blocking NF-κB, MAPK, and PI3K/Akt activation. Coptisine Sulfate inhibits cancer cells proliferation, induces DNA damage, G2/M phase cell cycle arrest, apoptosis, ROS production and mitochondrial dysfunction. Coptisine Sulfate inhibits *Rho/ROCK* pathway activation, reduces arrhythmia, limits cardiac injury marker release, reduces infarct size, and preserves cardiac function in rat myocardial ischemia/reperfusion models. Coptisine Sulfate downregulates HMGCR and upregulates LDLR and CYP7A1 to modulate cholesterol metabolism, reduces abnormal serum lipid levels, and promotes fecal bile acid excretion. Coptisine Sulfate be used for the research of cancer, hypercholesterolemia, Alzheimer’s disease, inflammatory disorders and cardiovascular disease .

HY-N12378

β-Patchoulene	Other Terpenoids Structural Classification Entada phaseoloides (L.) Merr. Terpenoids Labiatae Plants Source Classification	NF-κB Toll-like Receptor (TLR) PKA Epigenetic Reader Domain Keap1-Nrf2 Sirtuin AMPK Caspase FASTK ERK ROCK Apoptosis
β-Patchoulene is an orally active anti-inflammatory, antioxidant, and anti-apoptotic agent. β-Patchoulene inhibits the NF-κB, TLR4, and cAMP/PKA/CREB signaling pathways; activates the Sirt1/Nrf2 and AMPK signaling pathways; and targets Fas/FasL, Caspase-3, ERK1/2, *ROCK1/MLC2* for inhibition. β-Patchoulene regulates cytokine secretion, inflammatory cell infiltration, lipid peroxidation, cell polarization, gut microbiota, and lipid metabolism, restores barrier function, mitochondrial function, and cell viability, and exhibits repellent activity against Spodoptera exigua larvae. β-Patchoulene can be used in research related to various inflammatory, ischemic, fibrosis-associated diseases, as well as hepatocellular carcinoma .

HY-N12466

3′-O-Demethyl-4′-N-demethyl-4′-N-acetyl-4′-epi-staurosporine	Alkaloids Microorganisms Indole Alkaloids Source Classification	PKC p38 MAPK ROCK
3′-O-Demethyl-4′-N-demethyl-4′-N-acetyl-4′-epi-staurosporine (Compound 7) is an inhibitor of protein kinases, with IC₅₀s of 0.092, 0.26, 0.77 μM for PKC-α, ROCK, ASK1. 3′-O-Demethyl-4′-N-demethyl-4′-N-acetyl-4′-epi-staurosporine shows potent cytotoxicity against PC-3 cancer cells with an IC₅₀ value of 0.16 μM .

HY-N15301

Nocarnickelamide B	Microorganisms Ketones, Aldehydes, Acids Source Classification	ROCK Myosin
Nocarnickelamide B (Compound 2) is a linear peptide and *ROCK1/2* inhibitor. Nocarnickelamide B exhibits dual inhibitory activity against *ROCK1* and *ROCK2* with IC₅₀s of 14.9 μM and 21.9 μM, respectively. Nocarnickelamide B binds to the ATP-binding site. Nocarnickelamide B inhibits the activation of ROCK-regulated cytoskeletal contraction markers such as the myosin light chain. Nocarnickelamide B is potential for glaucoma reasearch .

HY-119925

Amaralin	Structural Classification Prosopis juliflora (Sw.) DC. Terpenoids Sesquiterpenes Plants Compositae Source Classification	Drug Intermediate
Amaralin is a sesquiterpene lactone with analgesic activity, which exists in the leaves and stems of Helenium amarum (Raf.) H. Rock. When administered subcutaneously, Amaralin produces analgesic effects in the mouse tail-flick test. When administered subcutaneously, Amaralin inhibits acetic acid-induced writhing syndrome in mice. Amaralin can be used for pain-related research .

HY-N12378A

α-Patchoulene	Structural Classification Entada phaseoloides (L.) Merr. Terpenoids Labiatae Sesquiterpenes Plants Source Classification	AMPK FASTK Sirtuin ROCK Keap1-Nrf2 Toll-like Receptor (TLR) Apoptosis PKA ERK NF-κB Epigenetic Reader Domain Caspase
α-Patchoulene is an orally active anti-inflammatory, antioxidant, and anti-apoptotic agent. α-Patchoulene inhibits the NF-κB, TLR4, and cAMP/PKA/CREB signaling pathways; activates the Sirt1/Nrf2 and AMPK signaling pathways; and targets Fas/FasL, Caspase-3, ERK1/2, *ROCK1/MLC2* for inhibition. α-Patchoulene regulates cytokine secretion, inflammatory cell infiltration, lipid peroxidation, cell polarization, gut microbiota, and lipid metabolism, restores barrier function, mitochondrial function, and cell viability, and exhibits repellent activity against Spodoptera exigua larvae. α-Patchoulene can be used in research related to various inflammatory, ischemic, fibrosis-associated diseases, as well as hepatocellular carcinoma .

Cat. No.	Product Name	Chemical Structure

HY-W700452

Y-27632-d4 hydrochloride hydrate

Y-27632-d₄ hydrochloride hydrate is the deuterium labeled Y-27632 hydrochloride hydrate (HY-10071A). Y-27632 hydrochloride hydrate is an orally active, ATP-competitive inhibitor of ROCK-I and ROCK-II, with Kis of 220 and 300 nM, respectively. Y-27632 hydrochloride hydrate attenuates Doxorubicin-induced apoptosis of human cardiac stem cells. Y-27632 hydrochloride hydrate also suppresses dissociation-induced apoptosis of murine prostate stem/progenitor cells. Y-27632 hydrochloride hydrate primes human induced pluripotent stem cells (hIPSCs) to selectively differentiate towards mesendodermal lineage via epithelial-mesenchymal transition-like modulation .

HY-15307S

Belumosudil-d7
Belumosudil-d₇ (KD025-d₇) is deuterium labeled Belumosudil. Belumosudil (KD025) is a selective inhibitor of *ROCK2* with IC₅₀s of 105 nM and 24 μM for ROCK2 and ROCK1, respectively. Anti-fibrotic properties .

Targets Recommended: ROCK

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-13257G

Thiazovivin	ROCK	Cancer
Thiazovivin (GMP) is Thiazovivin (HY-13257) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. Thiazovivin is a potent *ROCK* inhibitor .

HY-10583G

Y-27632 dihydrochloride 1 Publications Verification	ROCK	Neurological Disease Cancer
Y-27632 dihydrochloride (GMP) is the GMP level of Y-27632 dihydrochloride (HY-10583). GMP guidelines are used to produce Y-27632 dihydrochloride (GMP). GMP small molecules works appropriately as an auxiliary reagent for cell research manufacture. Y-27632 dihydrochloride is an orally active and ATP-competitive ROCK (Rho-kinase) inhibitor with antiepileptic effect .

HY-107614G

1-Oleoyl lysophosphatidic acid sodium 1-Oleoyl-sn-glycero-3-phosphate sodium; 1-Oleoyl-LPA sodium	LPL Receptor ROCK TGF-beta/Smad TGF-β Receptor	Neurological Disease Cancer
1-Oleoyl lysophosphatidic acid sodium (GMP) is the GMP-grade form of 1-Oleoyl lysophosphatidic acid sodium (HY-107614). GMP-grade small molecules serve as auxiliary reagents in cell therapy. 1-Oleoyl lysophosphatidic acid sodium is a bioactive lipid signaling molecule. 1-Oleoyl lysophosphatidic acid sodium inhibits lysoPLD-catalyzed hydrolysis of lysophosphatidylcholine and FS-3. 1-Oleoyl lysophosphatidic acid sodium activates LPA₁ and LPA₂, thereby triggering calcium mobilization, NFATc1 translocation, *Rho/ROCK* activation, Smad2/3 phosphorylation and c-Fos expression. 1-Oleoyl lysophosphatidic acid sodium induces anxiety-like, depression-like and hypoactivity phenotypes, regulates osteoclast cytoskeleton and viability, reduces osteoclast bone resorptive activity, and drives mesenchymal stem cell differentiation into myofibroblast-like cells. 1-Oleoyl lysophosphatidic acid sodium stimulates the secretion of transforming growth factor-β1 and stromal cell-derived factor-1. 1-Oleoyl lysophosphatidic acid sodium is applicable to research related to anxiety, depression and ovarian cancer .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks